Literature DB >> 22532675

Envelope variable region 4 is the first target of neutralizing antibodies in early simian immunodeficiency virus mac251 infection of rhesus monkeys.

Wendy W Yeh1, Laura M Brassard, Caroline A Miller, Aravind Basavapathruni, Jinrong Zhang, Srinivas S Rao, Gary J Nabel, John R Mascola, Norman L Letvin, Michael S Seaman.   

Abstract

A major goal of AIDS vaccine development is to design vaccination strategies that can elicit broad and potent protective antibodies. The initial viral targets of neutralizing antibodies (NAbs) early after human or simian immunodeficiency virus (HIV/SIV) infection are not known. The identification of early NAb epitopes that induce protective immunity or retard the progression of disease is important for AIDS vaccine development. The aim of this study was to determine the Env residues targeted by early SIV NAbs and to assess the influence of prior vaccination on neutralizing antibody kinetics and specificity during early infection. We previously described stereotypic env sequence variations in SIVmac251-infected rhesus monkeys that resulted in viral escape from NAbs. Here, we defined the early viral targets of neutralization and determined whether the ability of serum antibody from infected monkeys to neutralize SIV was altered in the setting of prior vaccination. To localize the viral determinants recognized by early NAbs, a panel of mutant pseudoviruses was assessed in a TZM-bl reporter gene neutralization assay to define the precise changes that eliminate recognition by SIV Env-specific NAbs in 16 rhesus monkeys. Changing R420 to G or R424 to Q in V4 of Env resulted in the loss of recognition by NAbs in vaccinated monkeys. In contrast, mutations in the V1 region of Env did not alter the NAb profile. These findings indicate that early NAbs are directed toward SIVmac251 Env V4 but not the V1 region, and that this env vaccination regimen did not alter the kinetics or the breadth of NAbs during early infection.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22532675      PMCID: PMC3416332          DOI: 10.1128/JVI.00107-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

1.  Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates.

Authors:  P D Kwong; R Wyatt; S Majeed; J Robinson; R W Sweet; J Sodroski; W A Hendrickson
Journal:  Structure       Date:  2000-12-15       Impact factor: 5.006

2.  Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization.

Authors:  Bimal K Chakrabarti; Wing-pui Kong; Bei-yue Wu; Zhi-Yong Yang; Jacques Friborg; Xu Ling; Steven R King; David C Montefiori; Gary J Nabel
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

3.  Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies.

Authors:  J R Mascola; G Stiegler; T C VanCott; H Katinger; C B Carpenter; C E Hanson; H Beary; D Hayes; S S Frankel; D L Birx; M G Lewis
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

4.  Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection.

Authors:  T W Baba; V Liska; R Hofmann-Lehmann; J Vlasak; W Xu; S Ayehunie; L A Cavacini; M R Posner; H Katinger; G Stiegler; B J Bernacky; T A Rizvi; R Schmidt; L R Hill; M E Keeling; Y Lu; J E Wright; T C Chou; R M Ruprecht
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

5.  Selection of genetic variants of simian immunodeficiency virus in persistently infected rhesus monkeys.

Authors:  D P Burns; R C Desrosiers
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

6.  Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro.

Authors:  P W Parren; P A Marx; A J Hessell; A Luckay; J Harouse; C Cheng-Mayer; J P Moore; D R Burton
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

7.  A replication-competent, neutralization-sensitive variant of simian immunodeficiency virus lacking 100 amino acids of envelope.

Authors:  Welkin E Johnson; Jennifer Morgan; Julie Reitter; Bridget A Puffer; Susan Czajak; Robert W Doms; Ronald C Desrosiers
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

8.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

9.  Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities.

Authors:  Welkin E Johnson; Hannah Sanford; Linda Schwall; Dennis R Burton; Paul W H I Parren; James E Robinson; Ronald C Desrosiers
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

10.  Correlation between env V1/V2 region diversification and neutralizing antibodies during primary infection by simian immunodeficiency virus sm in rhesus macaques.

Authors:  Brian J Rybarczyk; David Montefiori; Philip R Johnson; Ande West; Robert E Johnston; Ronald Swanstrom
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

View more
  5 in total

Review 1.  Immunopathogenesis of simian immunodeficiency virus infection in nonhuman primates.

Authors:  Joern E Schmitz; Birgit Korioth-Schmitz
Journal:  Curr Opin HIV AIDS       Date:  2013-07       Impact factor: 4.283

Review 2.  Using nonhuman primates to model HIV transmission.

Authors:  Christine M Fennessey; Brandon F Keele
Journal:  Curr Opin HIV AIDS       Date:  2013-07       Impact factor: 4.283

3.  High-Resolution Sequencing of Viral Populations during Early Simian Immunodeficiency Virus Infection Reveals Evolutionary Strategies for Rapid Escape from Emerging Env-Specific Antibody Responses.

Authors:  Sergio Ita; Alison K Hill; Evan C Lam; Fay J Dufort; Xiao Yang; Ruchi Newman; Sivan Leviyang; Ismael B Fofana; Welkin E Johnson
Journal:  J Virol       Date:  2018-03-14       Impact factor: 5.103

4.  Critical amino acids within the human immunodeficiency virus type 1 envelope glycoprotein V4 N- and C-terminals contribute to virus entry.

Authors:  Yan Li; Dan Yang; Jia-Ye Wang; Yuan Yao; Wei-Zhe Zhang; Lu-Jing Wang; De-Chun Cheng; Feng-Kun Yang; Feng-Min Zhang; Min Zhuang; Hong Ling
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

5.  Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability.

Authors:  Rosemarie D Mason; Hugh C Welles; Cameron Adams; Bimal K Chakrabarti; Jason Gorman; Tongqing Zhou; Richard Nguyen; Sijy O'Dell; Sabrina Lusvarghi; Carole A Bewley; Hui Li; George M Shaw; Zizhang Sheng; Lawrence Shapiro; Richard Wyatt; Peter D Kwong; John R Mascola; Mario Roederer
Journal:  PLoS Pathog       Date:  2016-04-11       Impact factor: 6.823

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.